Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. (NASDAQ: STIM) is a commercial stage medical technology and healthcare company focused on neurohealth and psychiatric disorders, and its news flow reflects this focus. The company develops and markets the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment used in office-based settings, and operates Greenbrook TMS treatment centers across the United States. News about Neuronetics often centers on clinical use of NeuroStar TMS, payer coverage decisions, and developments at its Greenbrook clinics.
Investors following STIM news can expect regular updates on quarterly financial and operating results, as the company reports revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue. Press releases also cover changes to its capital structure and credit facilities, such as amendments to its agreement with Perceptive Credit Holdings IV, LP, as well as at-the-market equity offerings and related capital-raising activities.
Company announcements frequently highlight health policy and reimbursement milestones, including expanded coverage for TMS therapy by New York State Medicaid and TRICARE West for specific patient populations with major depressive disorder. Neuronetics also reports on partnerships and agreements that expand access to NeuroStar TMS, such as an exclusive three-year collaboration with Elite DNA Behavioral Health, under which Neuronetics becomes the sole provider of TMS devices across that network and offers operational and patient-support services using the Greenbrook platform.
Additional STIM news items include participation in investor conferences, leadership and executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and publications of real-world clinical data from the NeuroStar outcomes databases. For readers tracking Neuronetics, this news page aggregates these developments so they can monitor financial performance, payer coverage trends, clinical evidence, and corporate actions related to NeuroStar TMS and Greenbrook treatment centers.
Neuronetics (NASDAQ: STIM) announced that Optum/United Healthcare/United Behavioral Health updated its Transcranial Magnetic Stimulation (TMS) clinical policy to allow psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer TMS where full practice authority (FPA) exists.
The change expands access to NeuroStar TMS across 26 states and Washington, D.C. and affects 34.8 million Optum/UHC/UBH commercial covered lives, increasing provider capacity for non-drug depression treatment.
Neuronetics (NASDAQ: STIM) responded to a public letter from Jorey Chernett at Pointillist Family Office dated April 6, 2026. The Company said the Board and management are committed to acting in all shareholders' best interests and regularly evaluate options to maximize shareholder value.
According to the Company, the Board reviewed the letter, values engagement with shareholders, and agrees the current valuation may not reflect the business strength; the Board is open to constructive engagement while executing strategic priorities to enhance long-term value.
Neuronetics (NASDAQ: STIM) announced that Steven E. Pfanstiel will resign as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the company and will remain through May 1, 2026 to support an orderly transition.
The company said the departure is not due to any dispute and that it has launched a search for a replacement. Neuronetics also reaffirmed its fiscal 2026 financial guidance previously provided on March 17, 2026.
Neuronetics (NASDAQ: STIM) largest independent shareholder, Jorey Chernett, delivered a letter on April 6, 2026 calling for an immediate, comprehensive review of strategic alternatives, including a potential sale of the Company's TMS business.
The letter cites a 14.12% ownership stake, argues that post-acquisition synergies have not materialized since December 2024, and claims applying comparable multiples implies 5–7x upside to current STIM equity value. Chernett urges the Board to engage advisors to evaluate all options and consider separating the clinic business as a standalone.
Neuronetics (NASDAQ: STIM) reported Q4 2025 revenue of $41.8M (up 86% YoY) and full year 2025 revenue of $149.2M (up 99% YoY), driven by the December 2024 Greenbrook acquisition and clinic revenue of $87.0M for 2025. Gross margin fell to 48.5% for 2025 and the company reported a $39.1M net loss. Cash totaled $34.1M at year-end. Guidance for 2026: revenue $160M–$166M, gross margin 47%–49%, operating expenses $100M–$105M.
Dan Reuvers will become CEO effective March 23, 2026; TRICARE West expanded TMS coverage for adolescents aged 15+.
Neuronetics (NASDAQ: STIM) appointed Dan Reuvers as President and Chief Executive Officer, effective March 23, 2026, and he will join the Board. He succeeds Keith Sullivan, who will step down March 23 and retire March 31, 2026. The company granted 1,500,000 RSUs vesting over three years as an inducement.
Reuvers brings 30+ years in medical devices, including scaling revenue at Tactile Medical from $187M to about $300M, and prior leadership at Integra LifeSciences. The RSU grant was approved under NASDAQ Listing Rule 5635(c)(4).
Neuronetics (NASDAQ: STIM) will release its fourth quarter 2025 financial and operating results before market open on Tuesday, March 17, 2026.
The company will host a live conference call at 8:30 a.m. Eastern Time the same day, available via webcast in listen-only mode; telephone registration is optional but recommended 10 minutes early.
Neuronetics (NASDAQ: STIM) reported selected preliminary unaudited results for Q4 and full-year 2025, showing Q4 revenue $41.8M (+86% as reported, +23% adjusted pro forma) and FY2025 revenue $149.2M (+99% as reported, +15% adjusted pro forma).
The company delivered positive operating cash flow $0.9M in Q4, shipped 49 NeuroStar Advanced Therapy systems in the quarter, and ended 2025 with $34.1M in total cash. Results assume the Greenbrook acquisition occurred January 1, 2024 with specified pro-forma adjustments.
Neuronetics (NASDAQ: STIM) said its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025 at 12:30 p.m. ET.
The presentation will be available via the conference portal to registered attendees.
Neuronetics (NASDAQ: STIM) announced that TriWest, the TRICARE regional administrator, updated its medical policy effective Nov 12, 2025 to cover NeuroStar TMS for adolescents aged 15 and older. The change applies immediately to TRICARE beneficiaries in 26 states, expanding access to a non‑drug, FDA‑cleared adolescent TMS option.
The release notes NeuroStar received FDA clearance for adolescents in 2024, cites an estimated 4.3 million U.S. adolescents aged 15–21 affected by major depression, and lists several private insurers that already cover NeuroStar.